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ABSTRACT 
About 60-70% of the drugs synthesized are poorly soluble and comes under BCS Class-II&IV. Now it is a challenging situation 
during the development of different dosage forms for pharmaceutical industries because solubility of the drug is the rate limiting 
step. Based on the solubility, the dissolution, bioavailability & therapeutic effect is dependent. To overcome this consequence a 
novel technique -Liquisolid compact is used by dissolving the poorly soluble drug in a non-volatile solvent that improves wettability 
& decreases the surface tension and ensures drug molecular dispersion in the formulation to increase the solubility of the drug. This 
admixture of drug loaded solution is blended with carrier adsorption & coating material (adsorption) that has free flowing and 
compressible powder properties. 
Keywords: BCS-Class II drug, Liquisolid Compact, Non-Volatile Liquid, Carrier, Coating material.  
 
Article Info: Received 19 Aug, 2018;   Review Completed 02 Sep 2018;   Accepted 05 Sep 2018;   Available online 15 Sep 2018 
Cite this article as: 
Naik NG, Shaym Sunder R, Sateesh Kumar M, A promising technique to improve the solubility by liquisolid 
compaction technology, Journal of Drug Delivery and Therapeutics. 2018; 8(5):56-61                                                             
DOI: http://dx.doi.org/10.22270/jddt.v8i5.1919   
*Address for Correspondence:  




Numerous potent lipophilic drugs show low oral 
bioavailability due to their poor aqueous solubility 
properties that falls under BCS- II- low solubility and 
high permeability¹. However low solubility and 
dissolution rate are main rate limiting factors². As per 
bioavailability is concerned, a drug is poor 
bioavailability is one with  
1. Poor aqueous solubility or slow dissolution rate in the 
biological fluid. 
2. No proper partition coefficient and thus poor 
permeation through the biomembrane.  




There are few approaches to overcome the 
bioavailability problem as listed below 
A.   Modification of formulation, manufacturing 
process/ changing the Physiochemical properties of drug 
according to pharmaceutical approach. 
B.   Alteration of chemical structure according to 
pharmacokinetic approach. 
C.   Route of drug administration may be changed from 
oral to parenteral route according to biological approach. 
As per the pharmacokinetic approach, chemical 
structure modification having number of draw backs. It 
is expensive and time consuming and also requires 
clinical study for longer time and the new chemical 
entity suffer from another pharmacokinetic disorders. 
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Finally the pharmaceutical approach will be dealt here 
with.  
The attempts whether optimizing the formulation, 
manufacturing process or drug physico- chemical 
properties that are mainly aimed at enhancement of 
dissolution rate as it is the major rate limiting step in the 
absorption of  most  drugs³. When the largest dose of a 
drug substance is soluble in lesser than 250 ml water 
such drugs are consider as highly soluble. Drug with 




The drug dissolution rate is directly proportional to 
solubility as per Noyes whitney equation and therefore 
solubility of a drug substance is a major factor. They are 
several methods to enhance the solubility, surface area 
and dissolution rate of poorly soluble drugs
5
. They are 
as follows: 
1. Complexation with cyclodextrins 
2. Solid dispersion 
3. Eutectic mixture 
4. Solvent deposition 
5. Hydrotrophy 
6. Use of surfactants 
7. Micronization technique 
8. Solvent evaporation 
9. Lyophilization technique 
10. Solid solution 
11. Co solvency 
Micronization is a common method to increase surface 
area but alter the flow property when drugs are 
encapsulated or tableted
6
. In complexation with 
cyclodextrins maximum drug loaded is relatively low 
and also depends upon the cavity of the dextrin
7,8
. Solid 
dispersion preparation requires special equipments likes 
spray dryer or fluid bed dryer
9
. Each and every 
technique has advantages and disadvantages. So to 
overcome the solution a novel technique-liquisolid 
compaction technology is developed to increase the 
solubility and dissolution rate of poorly soluble drugs.  
Liquisolid system: 
Liquid solid systems are powdered forms of liquid 
medication that exhibit acceptable or desirable 
flowability and compressibility properties. That term 
liquid medication refers to a solution or a suspension of 
a water insoluble drug in non-volatile solvent. 
Based on the type of liquid medication, liquisolid 
systems may be classified into three subgroups:  
1) Powdered drug solutions  
2) Powdered drug suspensions  
3) Powdered liquid drugs  
The first two may be produced from the conversion of 
drug solutions (e.g. Prednisolone solution in propylene 
glycol) or drug suspensions (e.g. gemfibrozil suspension 
in Polysorbate 80) and the latter from the formulation of 
liquid drugs (e.g. clofibrate, valproic acid, liquid 
vitamins, etc.) into liquisolid systems
10
. 
Based on the formulation technique used, liquisolid 
systems may be classified into two categories, namely,  
1) Liquisolid compacts  
2) Liquisolid Microsystems.  
Liquisolid compacts are prepared  by using the  below 
method to produce tablets or capsules, whereas the 
liquisolid Microsystems are based on a new concept 
which employs similar methodology combined with the 
inclusion of an additive, e.g., polyvinylpyrrolidone 
(PVP) in the liquid medication which is incorporated 
into the carrier and coating materials to produce an 
acceptably flowing admixture for encapsulation
11
. The 
technique of liquisolid compaction has been used 
successfully to improve the invitro release of poorly 










Components of liquisolid compaction 
formulation 
1. Poorly insoluble drugs: 
Examples: Bromohexine hydrochloride, Indomethacin, 
Prednisolone & Aceclofenac. 
 This technique is successfully applied for low dose 
BCS class II and class IV drugs which are poorly water 
soluble and have slow dissolution rate
16
. 
2. Non volatile solvents  
Examples: Polyethylene glycol 400, Polyethylene 
glycol 200,Tween 20,Tween 80,Synperonic PE, 
Cremophore EL, Captex 200,captex 355 & Polysorbate. 
Principle of Non volatile solvent: 
Non volatile solvents improve wetting properties where 
liquid vehicle acts as wetting agent or surface active 
agent. Therefore interfacial tension decreases between 
media and surface of the drug or decreases the contact 





Examples: starch, lactose, sorbitol, microcrystalline 
cellulose. 
Principle of carrier: Carrier involves in the sorption 
process of liquid medication that improves surface area 
due to adsorption of porous particle and also having 
adsorption property and matted fibers in interior 
contribute in liquid medication
18
. 
4. Coating material:                                                                                                          
Examples: Colloidal silica of various grades such as 
cab-o-sil –M5, aerosil 200, syloid 244FP,                                                                                       
Principle of coating material: A coating material forms a 
uniform film around the particles of carrier and prevents 
the aggregation of particles as well as reduces inter 
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5. Disintegrants: 
Examples: sodium starch glycollate, crosspovidone & 
crosscarmellose etc. 
Principle of Disintegrants: Disintegrants are the agents 
added to tablet formulation to promote the breakup of 
the tablet in to smaller fragments in an aqueous 
environment thereby increasing the available surface 




 Pre formulation studies of liquisolid compacts 
1. Determination of drug solubility in different non 
volatile solvents  
2. Angle of slide determination                                                                                  
3. Flowable liquid retention potential determination                                   
4. Calculation of liquid loading factor                                                      
5. Liquisolid compressibility (LSC) 
In the liquid solid compact formulation, flowability and 
compressibility are calculated by mathematical model of 
liquid solid system  to know the quantities of carrier and 
coating material that gives flowable liquid retention 
potential(Ø value) and compressible liquid retention 
potential (Ψ-number ) of powder21. 
1. Determination of drug solubility in different non 
volatile solvents:                                      
Saturated solutions are prepared by adding excess of 
drug to non volatile solvents and shaking them on a 
shaker for 48 hours and the solutions are filtered by 
whatman filter paper and analyzed by spectrophotometer 
and the best solubility solvent is selected
22
. 
2. Angle of slide determination:                     
Weighed amount of carrier is placed at one end of metal 
plate with a polished surface and gradually raised till the 
plate becomes angular to the horizontal at which powder 
is about to slide.  It is used to measure the flow 
properties of powders. The angle of 33° is optimum for 
flow of powder.  
3. Flowable liquid retention potential (Φ value) 
determination: 
It is defined as the maximum weight of liquid that can 
be retained per unit powder material in order to produce 
and acceptably flowing liquid/powder admixture. This Φ 
–value of powders may be determined using a new 
procedure- liquisolid flowability (LSF) test. The Ø value 
is used to calculate excipient quantities. Equation for 
this is as follows:  
Lf = Ø + Ø (1 / R)  
Where  
Ø and Ø are the constant Ø values of carrier and coating 
materials, respectively. By calculating Lf and W, can 
calculate the amount of Q and q required for liquisolid 
systems.  
4. Calculation of liquid loading factor (Lf)): 
It is defined as the ratio of weight of liquid medication 
(w) to weight of carrier material (Q). Different 
concentrations of nonvolatile solvents are taken and the 





W=ratio of weight of liquid medication  
Q= weight of carrier material  
The liquid load factor that ensures acceptable 
flowability (Lf), and can be measured by: 
Lf= (1/R)  
5. Liquisolid compressibility test (LSC): 
It is developed to determine Ψ values and involves steps 
such as preparing carrier coating material admixture 
systems, preparing several uniform liquid/powder 
admixtures to tablets, determining average hardness, 
measuring of average liquid content of crushed tablets, 
as well as determining plasticity, sponge index and Ψ24. 
 
Table 1: Liquisolid formulation parameters of various excipients with commonly used non volatile liquids 
Powder excipients 
Ø-Values Ψ- Numbers 
Propylene glycol PEG 400 Propylene glycol PEG 400 
Avicel PH 102 0.16 0.005 0.224 0.242 
Avicel PH 200 0.26 0.02 0.209 0.232 
Cab-O-Sil M5(silica) 
With Avicel PH 102 
3.31 3.26 0.560 0.653 
Cab-O-Sil M5(silica) 
With Avicel PH 102 
2.57 2.44 0.712 0.717 
 
Preparation of Liquid Solid Compacts 
This method involves first a mathematically calculated 
amount of pure drug weighed and dissolved in the 
solvent in a molecularly dispersed state. For attaining 
good flow properties trial and error methods were used 
i.e. changing the carrier: coating material ratio from 50:1 
to 5:1 ratios according to new mathematical model 
expressions proposed by Liao. This liquid medication is 
poured on the suitable amount of carrier material. The 
liquid medication is absorbed into the carrier material 
internally and externally and then a suitable disintegrant 
is added to this material. Finally, coating material is 
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added for dry looking, adherent to the carrier material 
for achieving good compression properties.  
Excipients possessing fine and highly adsorptive 
particles such as various types of amorphous silicon 
dioxide (silica) are most suitable for this step. Before 
compression or encapsulation, various ingredients such 
as lubricants, disintegrants or polymers, and binders, 
may be mixed with the finished liquid-solid systems to 





Figure 1:  Preparation of Liquisolid Compacts
 
Table 2: Examples of liquisolid compacts drugs 
Poorly soluble drugs Non volatile solvents Carrier and Coating material 
Piroxicam
26 
Tween 80 MCC and colloidal silica 
Ibuprofen
27 
PEG 400 MCC and colloidal silica 
Ketoprofen
28 
PEG 400 lactose and silica gel 
Naproxen
29 
Cremophor  EL,  Synperonic  PE/L61  and PEG-200 MCC and colloidal silica 
Valsartan
30 
Propylene glycol MCC and colloidal silica 
Etoricoxib
31 
PEG 400 MCC and colloidal silica 
Famotidine
32 
Propylene glycol MCC and colloidal silica 
Fenofibrate
33 
Propylene glycol MCC and colloidal silica 
Fenofibrate
34 
PEG 400 MCC and colloidal silica 
diclofenac sodium
35 




1. Flow properties of the liquid solid system: 
The flow properties of the liquid solid system are 
determined by angle of repose, carr’s index and hausner 
ratio. 
2.  Scanning electron microscopy:  
Scanning electron microscopy is used to assess the 
morphological characteristics of the poorly soluble 
drugs - carrier system and liquid solid compact. The 
sample is mounted  on double sided adhesive carbon 
tape on brass stubs and analyzed  and also confirms  the 
drug is totally solubilized in liquid solid system and this 
ensures the complete solubility. 
3.  X-Ray Powder diffraction (XRD) studies: 
 X-ray powder diffraction studies conducted to pure 
drug, liquisolid physical mixture. These samples are 
exposed to Cu-Kα radiation at a scan rate of 1.50 / min 
over the 2θ range of 4-400 0C. Generally, disappearance 
of characteristic peaks of drug in the liquisolid 
formulation and retaining peaks of carrier material is 
observed. This indicates that drug gets converted to 
amorphous form or in solubilized form in the liquisolid 
formulation.  
4. Differential Scanning Calorimetry (DSC): 
To determine the interaction between excipients used in 
the formulation. This will also indicate success of 
stability studies. If the characteristic peak for the drug is 
absent in the DSC thermogram, there is an indication 
that the drug is in the form of solution in liquisolid 




Post compression evaluation:  
Hardness: hardness of the tablet is determined by 
Monsanto hardness tester and Pfizer tester. It is 
expressed in Kg/cm².  
Friability:  In friability test, samples are counted and 
weighted then tumbled in rotating drums with baffles, 
when the process is stopped; samples are moved out 
from the instrument, wiped-off dust and weighted again. 
The difference between the weight before and after the 
process is determined as Friability and should not 
exceed 1%, which is considered an ideal percentage.  
In-vitro dissolution studies:  
Generally dissolution studies are carried out using 
dissolution test apparatus USP -II at 37°±5°C. Many 
researches reveal that at low drug concentration in liquid 
medication, more rapid release rates are observed
37
. 
Invivo evaluation of liquisolid powder or tablets: The 
improvement in oral bioavailability is confirmed by 
estimating the pharmacokinetic parameters in various 
animals such as rabbit, beagle dog and the results are 




1. Bio-Pharmaceutical classification class II drugs with 
high permeability, slightly or very slightly water soluble 
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and practically insoluble liquids and solid of numerous 
drugs can be formulated into liquisolid systems.  
2. Enhancement of bioavailability of an orally 
administered water insoluble drugs is achieved.  
3. This principle governs the drug delivery from 
liquisolid systems of powdered drug solutions and it is 
mainly responsible for the improved dissolution profiles 
exhibited by this preparations.  
4.  Liquisolid systems formulate into immediate release 
or sustained release dosage forms.  
5. Optimized sustained release, liquisolid tablets or 
capsules of water insoluble drugs demonstrate constant 
dissolution rates (zero order release).  
Demerits  
1. This technique is only for water insoluble drugs.  
2. However, for formulation of high dose insoluble 
drugs, the liquisolid tablet is one of the limitations of 
this technique.  
3. In order to achieve acceptable flowability and 
compactability for liquisolid powder formulation, high 
levels of carrier material and coating materials should be 
added. This will increase the weight of tablets to above 
one gram which makes them difficult to swallow. 
Therefore, it is impossible with conventional tablet 
methods to convert high dose to liquisolid tablets with a 
tablet weight of less than 50 mg.  
4. Dissolution profile enhancement occurs in the 
presence of low levels of hydrophilic carrier, where 
coating material is not significant.  
Limitations 
1. Not applicable for formulation of high dose insoluble 
drugs.  
2. If more amount of carrier is added to produce free-
flowing powder, the tablet weight increases to more than 
one gram which is difficult to swallow.  
3. This method on industrial scale and to overcome the 
problems of mixing small quantities of viscous liquid 
solutions onto large amounts of carrier material may not 
be feasible.  
CONCLUSION 
Liquisolid technique is a promising tool to improve the 
solubility, wettability of water insoluble drug and 
ensures the molecular dispersion of a drug in the 
formulation by blending the pure drug with non-volatile 
solvent, carrier and coating material modification of 
formulation. By use of certain agents also causes 
sustained release of drugs from the liquid solid 
compacts. 
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